Clinical trials: Non Small Cell Lung Carcinoma NSCLC
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
This is an open label phase 2 study to evaluate the combination of Vigil™ and nivolumab in advanced or metastatic NSCLC that is progressive on or after one prior platinum-based systemic therapy.
- Conditions
- Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02639234
- Testing
- Vigil™, Nivolumab
- Where
- 3 sites in United States
- Sponsor
- Gradalis, Inc.
Non-small Cell Lung Cancer
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
- Trial name
- NCT03758287
- Testing
- CT053PTSA, Gefitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Lung Cancer
A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.
- Trial name
- NCT00144053
- Testing
- Cisplatin+Vindesine+MMC/ concurrent radiation, Irinotecan+Carboplatin/concurrent radiation, Paclitaxel+Carboplatin/concurrent radiation
- Volunteers
- 450 people
- Sponsor
- West Japan Thoracic Oncology Group
Non-small-cell Lung Cancer
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least two prior lines of chemotherapy.
- Trial name
- NCT01124864
- Testing
- AUY922
- Where
- 22 sites in United States, Canada and 8 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
LKB1 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer: A Retrospective Cohort Study
The goal of this observational study is to investigate whether LKB1 alterations can serve as a clinically meaningful biomarker for predicting therapeutic response and survival outcomes in patients with non-small cell lung cancer…
- Trial name
- LKB1-NSCLC (NCT07710599)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Nonsquamous Nonsmall Cell Neoplasm of Lung
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
- Trial name
- ANGIOMET (NCT01814163)
- Testing
- paclitaxel, carboplatin and bevacizumab
- Where
- 20 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Lung Cancer Group
Carcinoma, Non-Small-Cell Lung
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study
This is a nationwide, multicenter and retrospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- SELECT-1 (NCT04397432)
- Where
- 19 sites in China
- Volunteers
- 878 people
- Sponsor
- Tian Xie
Non-Small Cell Lung Cancer, Artificial Intelligence (AI) in Diagnosis
AI-Based Prediction of Stage and Survival in Non-Small Cell Lung Cancer: A Retrospective Study
This study aims to evaluate the role of artificial intelligence (AI) in predicting disease stage and survival in patients diagnosed with non-small cell lung cancer (NSCLC).
- Trial name
- NCT07068139
- Testing
- AI-Based Predictive Modeling
- Volunteers
- 156 people
- Sponsor
- Hilkat Fatih Elverdi
Radiotherapy, Immunotherapy
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
- Conditions
- Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver
- Trial name
- NCT03589339
- Testing
- NBTXR3, SABR, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 145 people
- Sponsor
- Nanobiotix
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
- Conditions
- Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- NCT05873439
- Testing
- Genomically Guided Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
This is a single arm, one center, phaseⅡ study evaluating efficacy and safety of erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage ⅢA N2 NSCLC with activating EGFR mutation in exon 19 or 21.
- Trial name
- ML25444 (NCT01217619)
- Testing
- erlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Baohui Han
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell…
- Trial name
- NCT00139711
- Testing
- Irinotecan, Docetaxel
- Where
- 15 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Pfizer
Advanced Care Planning (ACP), ELDERLY PEOPLE
Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences
This randomized controlled trial examined whether an advance care planning (ACP) tabletop game ("Walking with Wishes") could improve the consistency of life-sustaining treatment preferences between older adults with lung cancer…
- Conditions
- Advanced Care Planning (ACP), ELDERLY PEOPLE, Lung Cancer (NSCLC)
- Trial name
- NCT06616909
- Testing
- ACP GAME, acp manual
- Where
- Taiwan
- Volunteers
- 124 people
- Sponsor
- National Taiwan University Hospital
Non Small Cell Lung Cancer (NSCLC)
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior…
- Trial name
- FLEX (NCT00148798)
- Testing
- cetuximab + cisplatin + vinorelbine, cisplatin + vinorelbine
- Where
- 118 sites in Argentina, Australia and 26 more
- Volunteers
- 1,861 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Carcinoma, Non-Small-Cell Lung
OMEGA, Local Ablative Therapy in Oligometastatic NSCLC
Oligometastatic lung cancer (OM-NSCLC) seems to be associated with a better prognosis than usual Stage IV non-small cell lung cancer when radical local therapy of all metastatic sites is administered but the impact of such an…
- Trial name
- OMEGA (NCT03827577)
- Testing
- Surgical removal of primary and/or of all oligometastases, Non-surgical LAT, Standard medical therapy
- Where
- Italy
- Volunteers
- 195 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Lung Cancer
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00016367
- Testing
- Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non Small Cell Lung Cancer
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Subjects will be eligible for this study if they are about to start on a drug called nivolumab for lung cancer. Some patients' cancers respond to nivolumab but a majority of patients do not.
- Trial name
- NO3DEXPL (NCT03371992)
- Testing
- Nivolumab, 3D-EX, Evaluation of Response by RECIST
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nilogen Oncosystems
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.